C12N 2830/001
Controllable enhancer/promoter combination
Official title: controllable enhancer/promoter combination
C12N2830/001 (Controllable enhancer/promoter combination) appears on 1,006 US grants and 1,521 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,006
- Published applications
- 1,521
- Assignees
- 755
- Inventors
- 3,117
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 5 | 0 |
| 1993 | 11 | 0 |
| 1994 | 11 | 0 |
| 1995 | 8 | 0 |
| 1996 | 21 | 0 |
| 1997 | 37 | 0 |
| 1998 | 50 | 0 |
| 1999 | 41 | 0 |
| 2000 | 44 | 0 |
| 2001 | 38 | 14 |
| 2002 | 46 | 57 |
| 2003 | 37 | 98 |
| 2004 | 20 | 80 |
| 2005 | 26 | 59 |
| 2006 | 27 | 64 |
| 2007 | 32 | 51 |
| 2008 | 16 | 48 |
| 2009 | 29 | 44 |
| 2010 | 33 | 59 |
| 2011 | 27 | 50 |
| 2012 | 25 | 46 |
| 2013 | 22 | 33 |
| 2014 | 36 | 30 |
| 2015 | 36 | 44 |
| 2016 | 31 | 38 |
| 2017 | 29 | 47 |
| 2018 | 31 | 44 |
| 2019 | 18 | 49 |
| 2020 | 38 | 60 |
| 2021 | 28 | 76 |
| 2022 | 23 | 83 |
| 2023 | 30 | 76 |
| 2024 | 30 | 95 |
| 2025 | 40 | 101 |
| 2026 | 25 | 75 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Conjugates of guide RNA-Cas protein complex22 Sep 2026US 12,742,162 B2
- Compositions and production of nicked closed-ended DNA vectors8 Sep 2026US 12,729,386 B2Generation Bio Co.
- Papaver somniferum plants with a modified transcription factor gene in the regulation of benzylisoquinoline alkaloids synthesis1 Sep 2026US 12,721,295 B2Sun Pharmaceutical Industries (Australia) Pty Ltd
- Enumeration of genetically engineered microorganisms by live cell counting techniques1 Sep 2026US 12,721,882 B2Synlogic Operating Company, Inc.
- Recombinant expression vector for catalase secretion and escherichia coli strain transformed therewith8 Oct 2026US 2026/0308603 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Single-sex chicken with toxin-antitoxin system1 Oct 2026US 2026/0293865 A1New York University
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Transcriptional recording by crispr spacer acquisition from rna1 Oct 2026US 2026/0297595 A1ETH Zurich
- Cell lines and methods for producing recombinant adeno-associated virus1 Oct 2026US 2026/0297616 A1Regents of the University of Minnesota
Most cited
By later US patents
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003
- Production of vascular endothelial cell growth factor406US 5,194,596 ACalifornia Biotechnology Inc. · 1993
- Regulation of endogenous gene expression in cells using zinc finger proteins395US 6,824,978 B1Sangamo BioSciences, Inc. · 2004
- Modulation of endogenous gene expression in cells383US 6,933,113 B2Sangamo BioSciences, Inc. · 2005
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003